AAM: Avalere study shows Medicare plans increase patient costs for generics
The Association for Accessible Medicines commented on an analysis released by Avalere showing that Medicare plans increase patient costs for generic medicines.
“Avalere's analysis demonstrates that Medicare Part D Plans continue to deny patients the full value of low-cost generic drugs,” said David Gaugh, interim president and CEO of AAM. “Fewer than half of all generic drugs are on generic formulary tiers. Plans are profiting from patients using generic drugs through higher copays and placement on brand formulary tiers, even as generic prices continue to fall. AAM encourages the Administration and Congress to ensure that Medicare beneficiaries receive the full value of low-cost generics.”
Avalere analyzed Plan D sponsors and the distribution of generic prescription drugs on the various tiers from 2016 to 2024. The company found sponsors placed a higher proportion of covered generic drugs on non-generic tiers over time. The analysis also found that a higher percentage of generic medicines have been placed on non-preferred tiers since 2016, and grew 20%, from 36% in 2016 to 56% in 2024.
[Read more: AAM commends HHS, FTC call for information, solutions on drug shortages]
AAM pointed out that in the last 10 years, the use of generic drugs has saved patients and the U.S. healthcare system almost $3 trillion dollars. "Medicare patients deserve the full benefit of the savings provided by generics and biosimilars," the organization said.
In Medicare Part D, medicines are covered on formulary tiers. A drug in a lower tier will have a lower copay than a drug in a higher tier. For example, on average a plan may charge as low as $0 for preferred generics on Tier 1, $5 for generics on Tier 2, $42 for products on Tier 3 and a percentage of the list price for drugs on Tiers 4 and 5.
AAM noted that the intent is to encourage seniors to use the lowest-cost option possible. Because generic drugs are significantly less expensive than their brand counterparts, they have historically been placed on the lowest tier.
[Read more: Challenges continue, but generics companies see a bright future with biosimilars]
The organization said that in recent years, as prices for generic medicines continue to fall, many Medicare Part D plans continue to place generics on higher tiers with higher copays.
"This forces seniors to pay more for lower-cost generic medications, and the copay is often significantly more than the cost of the medication," AAM said.